VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
DMRA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HomeStocksDMRAInstitutional Holders

DMRA logoDamora Therapeutics, Inc. (DMRA) Institutional Ownership

Q2 2026 13F Data|Updated 2026-11-18

✨

Institutional ownership remained relatively flat this quarter, with top 10 holders controlling 62.2% of institutional value.

Institutional Ownership
Can exceed 100% due to securities lending, short interest, and reporting timing differences.
200.0%$1.7B total value · 0.00 pp vs prior quarter
Smart Money Score
Based on ownership concentration, fund quality, buying/selling activity, ownership indicators, and institutional trend.
61 / 100Bullish
Institutions & Flow99 holders+33 net flow (+46 / -13)

AI Insights & Key Takeaways

  • Positive Institutional Flow (+33)
  • Viking Global Investors Lp maintains a significant position
  • Top 10 holders control 62.2% of institutional value
  • No Insider Signal

Top Institutional Holders of DMRA

Ranked by reported Q2 2026 13F market value

Top 10 Holders
62.2%
Top 25 Holders
91.3%

Share of total reported institutional value in DMRA held by the largest 10 / 25 filers.

#InstitutionShares HeldMarket ValueQoQ ChangeOwnership %% of Fund
1FMR LLC9.2M$240.1M+2.1%56.416%0.01%
2Fairmount Funds Management LLC8.7M$226.6M0.0%53.238%14.98%
3Avoro Capital Advisors LLC3.8M$98.4M0.0%23.115%0.88%

Quarterly Institutional Activity

Filings activity in DMRA during Q2 2026, grouped by how each filer changed its position.

OverviewNew Buyers46Added To41Trimmed8Exited13
  • JPMORGAN CHASE & CO$49.8M
  • VANGUARD PORTFOLIO MANAGEMENT LLC$9.5M
  • STEMPOINT CAPITAL LP

DMRA Institutional Ownership by Quarter

8 quarters of 13F filings · Δ columns show change vs prior quarter

QuarterInst. HoldersΔ HoldersOwnership %Δ OwnershipTotal 13F ValueΔ Value
Q2 202699+52%199.99%+0.00 pp$1.67B+15%
Q1 202665+282%199.99%+29.41 pp$1.45B+2211%
Q4 202517+42%170.58%+159.92 pp$63M+10629%
Q3 202512+20%10.66%+2.35 pp$1M+30%
Q2 20251017%8.31%0.62 pp$0M+2.1%
Q1 202512+9.1%

How DMRA Compares to Peers

Institutional ownership and quarterly buying activity across the largest Oncology Biotech peers.

TickerCompanyMarket CapInst. OwnershipHoldersNet Buyers − Sellers
FTHFaeth Therapeutics, Inc.$568M54.5%45+16
LONALeonaBio, Inc.$17M184.4%45+4
KYNBKyntra Bio, Inc.$15M26.9%29-4
CNSYCerenome, Inc.$5M4.8%24-5
NXTSNexentis Technologies Inc.$291013.3%9-1

DMRA — Frequently Asked Questions

Quick answers to the most common questions about buying DMRA stock.

What percentage of DMRA is owned by institutions?

Based on Q2 2026 13F filings, institutional ownership of Damora Therapeutics, Inc. stands at 200.0%, held across 99 reporting institutions.

Who is the largest institutional holder of DMRA?

FMR LLC is the largest reported institutional holder of DMRA, with approximately 9,232,979 shares worth $0.24B as of Q2 2026.

Is DMRA a hedge fund favorite?

Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of DMRA, including VIKING GLOBAL INVESTORS LP.

What is DMRA's Smart Money Score?

Our composite Smart Money Score for DMRA is 61 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

How many institutions bought DMRA this quarter?

46 institutions opened new positions in DMRA during Q2 2026, while 13 fully exited. 41 added to existing positions and 8 trimmed.

4Venrock Adviser, LLC3.6M$93.7M0.0%22.019%2.84%
5BlackRock, Inc.3.2M$82.2M+1321.6%19.321%0.00%
6FCPM III SERVICES B.V.2.4M$63.5M0.0%14.915%8.46%
7RA CAPITAL MANAGEMENT, L.P.2.4M$62.4M+0.0%14.663%0.54%
8VIKING GLOBAL INVESTORS LP2.3M$60.1M0.0%14.121%0.17%
9Jupiter Topco LLC2.3M$59.3M—13.948%0.02%
10Remedium Capital Partners, LLC2.0M$53.2M0.0%12.498%11.78%
11Commodore Capital LP1.9M$50.4M0.0%11.848%3.00%
12JPMORGAN CHASE & CO2.1M$49.8M—12.581%0.00%
13BRAIDWELL LP1.6M$42.1M+81.1%9.901%1.56%
14Bellevue Group AG1.6M$42.1M-29.5%9.892%0.89%
15STATE STREET CORP1.5M$40.2M+740.3%9.443%0.00%
16a16z Capital Management, L.L.C.1.2M$32.2M0.0%7.553%0.23%
17BALYASNY ASSET MANAGEMENT L.P.1.2M$32.0M-15.1%7.510%0.04%
18PERCEPTIVE ADVISORS LLC1.2M$31.8M0.0%7.473%0.48%
19WELLINGTON MANAGEMENT GROUP LLP1.1M$27.5M0.0%6.465%0.00%
20Blackstone Inc.1.0M$26.1M+99.2%6.128%0.07%
21Cormorant Asset Management, LP1.0M$26.0M-34.4%6.110%1.33%
22GEODE CAPITAL MANAGEMENT, LLC965K$25.1M+300.4%5.899%0.00%
23Siren, L.L.C.900K$23.4M0.0%5.499%0.47%
24UBS Group AG840K$21.9M+423.8%5.134%0.00%
25Vestal Point Capital, LP575K$15.0M-4.2%3.513%0.35%

denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in DMRA — a direct measure of their conviction.

$5.6M
  • CITADEL ADVISORS LLC$4.3M
  • Bank of New York Mellon Corp$3.9M
  • Nuveen, LLC$3.9M
  • Swiss National Bank$1.9M
  • RHUMBLINE ADVISERS$1.7M
  • ALLIANCEBERNSTEIN L.P.$1.4M
  • DEUTSCHE BANK AG\$1.4M
  • ADAGE CAPITAL PARTNERS GP, L.L.C.$1.3M
  • WELLS FARGO & COMPANY/MN$1.2M
  • 8.93%
    +0.04 pp
    $0M
    33%
    Q4 202411+10%8.89%+0.84 pp$1M58%
    Q3 202410—8.05%—$2M—

    Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.

    How is institutional ownership of DMRA changing?

    DMRA institutional ownership rose by 0.00 percentage points quarter-over-quarter, with a net change of +34 holders.

    How concentrated is DMRA ownership among the top holders?

    The top 10 institutions account for 62.2% of all reported 13F value in DMRA, and the top 25 account for 91.3%.

    How does DMRA compare to Oncology Biotech on institutional ownership?

    Across the largest Oncology Biotech peers, institutional ownership levels are: FTH (54.5%), LONA (184.4%), KYNB (26.9%), CNSY (4.8%), NXTS (3.3%). See the peer comparison table on this page for net buyer activity by company.

    Where does this DMRA institutional ownership data come from?

    All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.

    DMRADamora Therapeutics, Inc.
    $22.98$1.5B
    Overview & Tools
    OverviewChart Terminal ↗Visualize
    Valuation & Forecasts
    Valuation ModelsEstimatesDCF Model
    Price & Analyst Data
    Analyst TargetsPrice History
    Financial Statements
    Income StatementBalance SheetCash FlowRatios & Margins
    Performance
    P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
    Discovery & Screens
    Live BreakoutsStock ScreenerOwnership